Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis

Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis

ObjectivesNeoadjuvant chemoimmunotherapy is the optimal choice in the treatment of NSCLC; however, the optimal number of therapeutic cycles remains unclear. The primary aim of this study was to determine the optimal number of neoadjuvant therapeutic cycles in NSCLC.MethodsThis study was a real-world...

Full description

Bibliographic Details
Main Authors: Baihua Zhang, Xiaotong Guo, Ran Jia, Zhan Wang, Jie Wu, Xiaoyan Chen, Jigang Li, Desong Yang, Xu Li, Wenxiang Wang, Qin Xiao
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
neoadjuvant chemoimmunotherapy
treatment cycles
adverse events
morbidity
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1200625/full

Similar Items

Similar Items